Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026
Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026
Company Deals

Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform

Fineline Cube Jun 20, 2023

Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...

Company Deals

Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics

Fineline Cube Jun 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...

Company

Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor

Fineline Cube Jun 20, 2023

Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit...

Company Drug

Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China

Fineline Cube Jun 20, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...

Company Drug

Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion

Fineline Cube Jun 20, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Deals

Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations

Fineline Cube Jun 20, 2023

Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has...

Company Deals

Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement

Fineline Cube Jun 20, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...

Company Drug

Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance

Fineline Cube Jun 20, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals

United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology

Fineline Cube Jun 20, 2023

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...

Company Deals

Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project

Fineline Cube Jun 20, 2023

Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...

Company Deals R&D

Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement

Fineline Cube Jun 20, 2023

China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman...

Company Drug

WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders

Fineline Cube Jun 20, 2023

China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National...

Company Drug

Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial

Fineline Cube Jun 19, 2023

China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug...

Company

AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions

Fineline Cube Jun 19, 2023

According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ:...

Company Drug

TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody

Fineline Cube Jun 19, 2023

China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US...

Company Drug

IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders

Fineline Cube Jun 19, 2023

China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved...

Company Deals

Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics

Fineline Cube Jun 19, 2023

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully...

Company Deals

Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration

Fineline Cube Jun 19, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with...

Company Drug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

Fineline Cube Jun 19, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...

Company Deals

Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes

Fineline Cube Jun 19, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...

Posts pagination

1 … 468 469 470 … 621

Recent updates

  • Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials
  • InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials
  • Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China
  • Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication
  • Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.